Andrew has significant investment experience in the healthcare sector. He is currently an investor on the Private Transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Andrew has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and as presented his research at numerous medical and surgical conferences. Andrew holds an MD from the Mayo School of Medicine, an MPH from the Harvard University School of Public Health, and an MBA from Harvard Business School.
Cameron Wheeler, PhD
Cameron is a Principal on the Private Transactions team at Deerfield. He joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years, where he was responsible for corporate development and commercial strategy. He was instrumental in the founding, building, and the eventual public offering of Eleven Biotherapeutics. Prior to Eleven, Cameron was at Third Rock Ventures, a Boston-based venture capital firm focused on launching and building life science companies. While at Third Rock, Cameron gained business development and operating experience as a member of the founding team of Constellation Pharmaceuticals. Cameron holds a PhD and SM in Biological Engineering and an SB in Mechanical Engineering from Massachusetts Institute of Technology.
Jose Antonio Mesa Cejudo
Caixa Capital Risc
Jose Antonio is Investment Director at Caixa Capital Risc where he is responsible for the analysis, negotiation and deal structuring process for the life science, biotechnology and medical technology segments. He currently serves on the board of directors at Sanifit, STAT Diagnostica, MedLumics, Aelix Therapeutics and Inbiomotion. Jose has more than ten years of experience in investment and specializes in the creation and growth of life sciences companies. His prior experience includes the business development department at Genzyme Corporation and the technology portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation. Jose holds a MSc in Genetics and a MSc in Corporate Finance from the Universidad Complutense, Madrid (UCM), MBA and PDD from IESE Business School.
Eladio Crego Gil
Eladio is Managing Director at EFT Consulting and is responsible for the Proof of Concept Fund of the Barrié Foundation. He works with multiple startups, helping entrepreneurs set up technology-based innovative businesses, and currently serves as CFO at Teimas Desenvolemento and Torus Software Solutions. Eladio is an evaluator at the SME Instrument and Fast Track to Innovation programs of the European Commission. He previously worked as an Investment Manager at venture capital companies Uninvest/Unirisco where he managed more than ten investments in biotech and new materials startups across Spain. Eladio has a Program for Management Development degree from ESADE Business School, a M.B.A from Abanca Business School and a BA in Economics from the University of Santiago de Compostela.